Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Recruitment status was Recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining methotrexate with vinblastine may be effective treatment for neurofibromatosis type 1 associated with progressive plexiform neurofibromas.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have neurofibromatosis type 1 associated with progressive plexiform neurofibromas.
Neurofibromatosis Type 1
Drug: vinblastine sulfate
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Vinblastine/Methotrexate For Severe Progressive Plexiform Neurofibromas: A Phase II Study|
- Time to disease progression after 6 months [ Designated as safety issue: No ]
- Objective response rate [ Designated as safety issue: No ]
- Toxicity [ Designated as safety issue: Yes ]
- Quality of life parameters as measured by standard, validated, age-calibrated performance, pain, and mood scales [ Designated as safety issue: No ]
- Perception of treatment impact on patient self-identified worst symptoms as measured by numeric assessment tools [ Designated as safety issue: No ]
|Study Start Date:||February 2001|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
- Determine the effect of chronic vinblastine and methotrexate on time to disease progression in children or young adults with progressive plexiform neurofibroma associated with neurofibromatosis type 1.
- Determine the objective response rate in patients treated with this regimen.
- Determine the toxic effects of this regimen in these patients.
- Determine the quality of life of patients treated with this regimen.
OUTLINE: Patients are stratified according to tumor status (severely debilitating and/or life-threatening vs cosmetically disfiguring).
Patients receive methotrexate and vinblastine IV weekly for 26 weeks and then every 2 weeks for 26 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and then every 3 months during study participation.
Patients are followed every 3 months until disease progression.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within approximately 3 years.
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Jean B. Belasco, MD 215-590-3129|
|Study Chair:||Jean B. Belasco, MD||Children's Hospital of Philadelphia|